This program project application has as its central theme the idea that the cell cycle may provide targets that could be manipulated to alter the therapeutic outcome in cancer treatment. Assessing the validity of the this idea is totally dependent on the adequacy of the conditions used for the experimental assays. The most critical aspect of this is the cell synchrony and flow cytometry. Because adequate flow cytometry is central to all five projects, the decision has been made to centralize all flow analysis and have the bulk of the flow carried out by the most experienced team using a single facility. This ensures that all projects have access to the highest quality service and that the conditions and the form of analysis used throughout the entire project will be comparable. The team leader of this core, Dr. Bernard, is the most experienced scientist is QA aspects of flow cytometry and in synchronization procedures. The costs associated with core related to service center cost changed by the Cancer Center at the University of Pennsylvania for running flow samples. Additional funds have been requested to purchase a microcomputer and software for data analysis. Our experience is that the time available on the Cancer Center's computer for data analysis of large flow runs is frequently the bottleneck that prevents more rapid experimental progress. Frequently, the design of future experiments is dependent on having the analysis completed on previous runs. In time is unavailable for data analysis after data collection, it often results in part of the laboratory standing idle until the analysis is complete. Access to out own computer and software will eliminate this bottleneck.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pennsylvania
United States
Zip Code
Qayum, Naseer; Im, Jaehong; Stratford, Michael R et al. (2012) Modulation of the tumor microvasculature by phosphoinositide-3 kinase inhibition increases doxorubicin delivery in vivo. Clin Cancer Res 18:161-9
Higgins, Geoff S; Prevo, Remko; Lee, Yin-Fai et al. (2010) A small interfering RNA screen of genes involved in DNA repair identifies tumor-specific radiosensitization by POLQ knockdown. Cancer Res 70:2984-93
Dorsey, Jay F; Mintz, Akiva; Tian, Xiaobing et al. (2009) Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and paclitaxel have cooperative in vivo effects against glioblastoma multiforme cells. Mol Cancer Ther 8:3285-95
Hamilton, Julie; Grawenda, Anna M; Bernhard, Eric J (2009) Phosphatase inhibition and cell survival after DNA damage induced by radiation. Cancer Biol Ther 8:1577-86
Hamilton, Julie; Higgins, Geoff; Bernhard, Eric J (2009) Conventional radiotherapy or hypofractionation? A study of molecular changes resulting from different radiation fractionation schemes. Cancer Biol Ther 8:774-6
Qayum, Naseer; Muschel, Ruth J; Im, Jae Hong et al. (2009) Tumor vascular changes mediated by inhibition of oncogenic signaling. Cancer Res 69:6347-54
Al-Assar, Osama; Muschel, Ruth J; Mantoni, Tine S et al. (2009) Radiation response of cancer stem-like cells from established human cell lines after sorting for surface markers. Int J Radiat Oncol Biol Phys 75:1216-25
Plastaras, John P; Dorsey, Jay F; Carroll, Kristina et al. (2008) Role of PI3K/Akt signaling in TRAIL- and radiation-induced gastrointestinal apoptosis. Cancer Biol Ther 7:2047-53
Finnberg, Niklas; Wambi, Chris; Ware, Jeffrey H et al. (2008) Gamma-radiation (GR) triggers a unique gene expression profile associated with cell death compared to proton radiation (PR) in mice in vivo. Cancer Biol Ther 7:2023-33
Prevo, Remko; Deutsch, Eric; Sampson, Oliver et al. (2008) Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity. Cancer Res 68:5915-23

Showing the most recent 10 out of 98 publications